Gallwitz Baptist
Professor of Medicine, Department of Medicine IV, Eberhard Karls University, Tübingen, Germany.
Eur Endocrinol. 2014 Aug;10(2):98-99. doi: 10.17925/EE.2014.10.02.98. Epub 2014 Aug 28.
Safe and effective therapies for type 2 diabetes are needed to reduce the burden of late complications and costs associated with this chronic disease. Hypoglycaemia and body weight gain are side effects and limitations of the therapy with insulin and/or sulphonylureas. Recently, the combination of glucagon-like peptide-1 (GLP-1) receptor agonists and insulin has become available, which is associated with good efficacy and less risk for hypoglycaemia and weight gain. This editorial discusses the strategies to escalate treatment in type 2 diabetes in view of this novel combination and discusses its placement within the therapeutic algorithm of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Recent developments to simplify this combination therapy are also dealt with.
需要安全有效的2型糖尿病治疗方法来减轻与这种慢性病相关的晚期并发症负担和成本。低血糖和体重增加是胰岛素和/或磺脲类药物治疗的副作用和局限性。最近，胰高血糖素样肽-1（GLP-1）受体激动剂与胰岛素的联合用药已可使用，其疗效良好，低血糖和体重增加风险较低。本社论鉴于这种新的联合用药方式，讨论了2型糖尿病强化治疗的策略，并讨论了其在美国糖尿病协会（ADA）和欧洲糖尿病研究协会（EASD）治疗算法中的位置。还探讨了简化这种联合治疗的最新进展。
